Clinical Trial Update: A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing two dosing strengths of Sublingually Org 5222 (asenapine) to assess safety and equivalence in schizophrenia or schizoaffective disorder;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Sublingually Org 5222 (asenapine)

Snippet

Sponsor: Organon and Co | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2010-10-13